Press release archive - GSK
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
Press releases | GSK US
New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy in older adults, including those with underlying medical …
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
LONDON, Feb 15 (Reuters) - GSK (GSK.L) said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and …
GSK's experimental drug shows promise in reducing severe …
May 21 (Reuters) - GSK's (GSK.L) experimental drug met its primary goal of reducing asthma attacks in a late-stage trial, marking a bright spot for a treatment that the British drugmaker …
GSK lifts annual forecasts again, powered by strong vaccine launch
Nov 1 (Reuters) - GSK (GSK.L) raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its respiratory syncytial virus (RSV) vaccine in the...
GlaxoSmithKline News | GSK News - NewsNow
NewsNow aims to be the world's most accurate and comprehensive aggregator of GlaxoSmithKline news, covering the latest share price, company announcements, vaccine …
GSK Raises Outlook, Looks to New Medicines to Fuel Growth
Jul 26, 2023 · GSK Plc raised its guidance for the year after a strong start to 2023 as it prepares to begin selling one of the first vaccines to prevent a common respiratory virus. Sales will …
GSK delivers strong 2022 performance with full year sales of £29.3 ...
Feb 1, 2023 · Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines. Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, …
For media and investors only - GSK
Jun 23, 2021 · At an update to investors today, GlaxoSmithKline plc (GSK LSE & NYSE) will provide details of its strategy, outlook for growth and plans to create shareholder value, …